Keyphrases
Osteoporotic Fractures
44%
Mild Hypertension
44%
Sputum
44%
Myasthenia Gravis
44%
Antibiotic Use
44%
Cluster Randomized Trial
44%
Length of Hospital Stay
44%
Feedback Method
44%
Population-based Cohort Study
44%
Dipeptidyl peptidase-4 (DPP-4)
44%
Measurement Method
44%
Hospital Compare
44%
Pneumonia
44%
Amoxicillin
44%
Acute Exacerbation of COPD (AECOPD)
44%
Severe Hypertension
44%
Hypertensive Disorders of Pregnancy
44%
β-lactamase Activity
44%
Moderate to Severe
44%
Tailored Treatment
44%
Preeclampsia
44%
Oral Glucocorticoids
44%
Hypertension
33%
Antihypertensive Medication
33%
Gestational Hypertension
33%
Osteoporotic Fracture Risk
33%
MIC90
31%
Antidiabetic Drugs
26%
Non-insulin
26%
Randomized Controlled Trial
22%
INIS
patients
100%
risks
96%
antibiotics
53%
comparative evaluations
51%
populations
49%
diseases
48%
adjustments
46%
hypertension
44%
fractures
44%
feedback
44%
concentration
44%
pregnancy
44%
pneumonia
44%
clinical trials
44%
glucocorticoids
44%
length
44%
hospitals
44%
drugs
43%
data
34%
interventions
31%
insulin
29%
women
20%
doses
19%
control
17%
growth
16%
therapy
15%
diabetes mellitus
14%
cardiac output
12%
implementation
11%
tools
11%
Pharmacology, Toxicology and Pharmaceutical Science
Maternal Hypertension
44%
Myasthenia gravis
44%
Preeclampsia
44%
Glucocorticoid
44%
Cohort Study
44%
Fragility Fracture
44%
Beta Lactamase
44%
Amoxicillin
44%
Borderline Hypertension
44%
Dipeptidyl Peptidase IV Inhibitor
44%
Chronic Obstructive Lung Disease
44%
Forward Heart Failure
33%
Antihypertensive Agent
33%
Randomized Controlled Trial
26%
Antidiabetic Agent
26%
High Output Heart Failure
22%
Non Insulin Dependent Diabetes Mellitus
13%
Alpha Adrenergic Receptor Stimulating Agent
11%
Proteinuria
11%
Beta Adrenergic Receptor Blocking Agent
11%
Maternal Disease
11%
Case-Control Study
11%
Disease Exacerbation
11%
Calcium Channel Blocker
11%
Hypertensive Agent
11%
Dihydropyridine
11%
Infection
9%
Comorbidity
8%
Clavulanic Acid
5%
Infectious Agent
5%